Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of “Moderate Buy” from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $39.00.

A number of analysts have recently issued reports on COLL shares. Truist Financial increased their price target on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, February 26th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 29th. Piper Sandler reissued an “overweight” rating and set a $39.00 target price (up previously from $37.00) on shares of Collegium Pharmaceutical in a research note on Friday, February 23rd. Jefferies Financial Group restated a “hold” rating and issued a $37.00 price objective (up previously from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $40.00 target price on shares of Collegium Pharmaceutical in a research note on Thursday.

Insider Activity

In related news, EVP Scott Dreyer sold 23,560 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $32.28, for a total value of $760,516.80. Following the transaction, the executive vice president now owns 111,322 shares in the company, valued at approximately $3,593,474.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.69% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in shares of Collegium Pharmaceutical by 4.6% in the 2nd quarter. BlackRock Inc. now owns 6,078,319 shares of the specialty pharmaceutical company’s stock worth $130,623,000 after acquiring an additional 266,330 shares during the period. Vanguard Group Inc. increased its holdings in Collegium Pharmaceutical by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 2,306,529 shares of the specialty pharmaceutical company’s stock valued at $46,962,000 after buying an additional 19,112 shares during the period. Pacer Advisors Inc. raised its stake in shares of Collegium Pharmaceutical by 68.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after buying an additional 883,380 shares in the last quarter. State Street Corp lifted its holdings in shares of Collegium Pharmaceutical by 6.3% during the 2nd quarter. State Street Corp now owns 1,390,693 shares of the specialty pharmaceutical company’s stock worth $24,643,000 after acquiring an additional 82,526 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Collegium Pharmaceutical by 1.1% in the first quarter. Renaissance Technologies LLC now owns 1,270,118 shares of the specialty pharmaceutical company’s stock valued at $25,860,000 after acquiring an additional 13,800 shares during the period.

Collegium Pharmaceutical Price Performance

COLL stock opened at $35.71 on Friday. The firm has a 50-day moving average of $36.69 and a two-hundred day moving average of $30.39. Collegium Pharmaceutical has a one year low of $20.83 and a one year high of $40.95. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. The firm has a market capitalization of $1.17 billion, a PE ratio of 30.26 and a beta of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.20 by $0.25. The business had revenue of $149.75 million during the quarter, compared to analysts’ expectations of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. On average, analysts forecast that Collegium Pharmaceutical will post 5.63 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.